ABSTRACT BACKGROUND AND PURPOSE: Although targeted by radiotherapy, recurrence in glioblastoma occurs
INTRODUCTION
Brain tumours are an expanding research area with a significant population burden. Glioblastomas are the most prevalent primary brain tumours, and one of the leading cancers in terms of years of life lost [1] . These tumours tend to recur despite maximal surgical resection of the contrast enhancing region of the tumour. This is followed by radiotherapy targeted at the surroundings of the resection area and combined with temozolomide chemotherapy [2] . Despite this, recurrence is still inevitable, happening even in all patients with a total resection of the contrast enhancing tumour and subsequent chemoradiotherapy. Recurrence occurs within or directly adjacent to the resection area in up to 90% [3] , likely due to the infiltrative nature of the tumour spreading beyond the contrast enhancing region [4] .
Recent studies demonstrated the potential of apparent diffusion coefficients (ADC) values for evaluating tumour recurrence. In a group of 20 brain tumour patients of which 7 had a glioblastoma, early changes in functional diffusion maps could be used to predict treatment response in patients treated with radiotherapy, chemotherapy or a combination of both [5] . Functional diffusion maps also identified response patterns in patients with glioblastomas treated with boron neutron capture therapy [6] . This was further supported in a rat glioblastoma model showing a correlation between histological decline in tumour cell density and increase in ADC days after the start of chemotherapy [7, 8] , which also correlated for spatial heterogeneity of ADC response and tumour cell density [8] .
Correlation between cell density and ADC has also been demonstrated in patients with untreated glioblastomas [9] .
Studies that assess ADC changes after radiotherapy are scarce. Studies in glioblastoma patients, of whom less than 50% received a total resection, showed an increase of ADC values postradiotherapy in comparison with preradiotherapy values in the residual contrast enhancing tumour and in the surrounding T2-hyperintens area [10, 11] . This was also related to survival in both studies [10, 11] .
However, as advanced surgical techniques such as neuronavigation and intraoperative 5-aminolevulinic acid (5-ALA) fluorescence guidance [12] allow resection of more than 90% of the contrast enhancing tumour volume, assessment of ADC values in this contrast enhancing region is of little practical relevance. Similarly, the large area of T2-hyperintense tumour is composed of both infiltrating tumour and vasogenic oedema. It thus can extend far beyond the original contrast enhancement and thus also beyond the periresection area where tumour recurrence is most likely to occur [3] .
This prompted us to assess the ADC values specifically in a smaller periresection area using pre-and postradiotherapy MRI scans in patients with a glioblastoma treated with surgical resection and standard concomitant and adjuvant chemoradiotherapy.
METHODS

Patient inclusion criteria
Patients with a newly diagnosed cerebral glioblastoma were included in this study. Patients were collected consecutively from 2010-2014. We included all patients with MRI follow up data from a initial cohort designed for a preoperative imaging study. Exclusion criteria were previous cranial surgery, previous cerebral radiotherapy, a known other primary tumour or follow-up outside our hospitals. Patients with a glioblastoma crossing the midline were not excluded. We included 14 patients (see Table 1 for general characteristics). Tumour location was defined as previously described [13] . All patients were on a stable dexamethasone dose and had a Karnofsky performance status ≥70. Surgical resection was performed using neuronavigation (StealthStation, Medtronic) and 5-ALA fluorescence guidance with the aim of maximal resection. Surgery was followed by standard concomitant chemoradiotherapy and adjuvant chemotherapy [2] starting 4 weeks after surgery.
Radiotherapy consisted of 60 Gy following the EORTC protocol with 60Gy in 30 fractions (2Gy fractions given once daily for five days a week over a six week period) [14] . Radiotherapy was delivered to the resection margin with a total margin of 3 cm in all patients. Follow-up MRI scans were collected directly after surgery, as well as pre-and postradiotherapy. The postoperative MRI was performed <72 hours after the operation. Direct preradiotherapy MRI was on average 21 days after the operation (range 14-32), while postradiotherapy MRI was on average 87 days (2.9 months) thereafter (range 77-96 days; 2.6-3.2 months). As preradiotherapy scans were missing in 3 patients, data concerning this time point was based on 11 patients, while other analyses were done on all 14 patients. Progression free survival and overall survival data were established based on medical records. Progression free survival was defined according to the RANO criteria [15] . 
Statistical analysis
In general, direct postoperative ADC values were similar to direct preradiotherapy. We therefore used preradiotherapy ADC values as primary baseline for comparison to postradiotherapy images. In addition, we compared the direct postoperative images with the postradiotherapy images as a preradiotherapy ADC is not acquired as standard in all clinical practices. Histogram analysis was used testing the mean, standard deviation, skewness and kurtosis. Skewness indicates the asymmetry of the distribution, while kurtosis represents the width and height of a distribution. Both represent the heterogeneity of a distribution, but in a different way, meaning that both can be normal of abnormal independent from each other. A two-way within subject analysis of variance was conducted to assess ADC values at different distances from the resection cavity using five factors starting with 0-5 mm from the resection cavity with 5 mm increments up to 20-25 mm from the resection cavity. Two time points were entered as factor (before and after radiotherapy). A similar analysis of variance was conducted for directly postoperative versus postradiotherapy. Mauchly's test of sphericity was used to test the sphericity for the main effect of distance and interaction between time and distance. As the assumption of sphericity was violated in all cases, we used Greenhouse-Geisser corrected output for all analyses of variance. Post-hoc comparisons used a paired t-test or Wilcoxon-signed rank test depending on the normality. The normality was tested using the Shapiro-Wilk test.
We further investigated the predictive value of the increase of the postradiotherapy ADC of the 0-5 mm area for the progression free survival and overall survival, first using a univariate Cox regression Two-sided p-values were used throughout. All statistical tests were performed using SPSS version 22
(IBM Inc., New York, USA).
RESULTS
Histogram analysis
Group mean, standard deviations, skewness and kurtosis of the patients mean of the periresection voxels are demonstrated ( Figure 2 ).
Mean ADC values at different distances from the resection cavity showed a significant interaction 
Survival analysis
The increase in ADC value postradiotherapy in comparison to preradiotherapy for the 0-5 mm area did not predict an increase in progression free survival (HR=0.414, p=0.711) or overall survival (HR=0.224, p=0.692). This did not change significantly after adjusting for age and MGMT status with a multivariate Cox regression model.
DISCUSSION
This is the first study to selectively analyse periresectional change of ADC values, as previous research has only looked at the large high T2 area [10, 11] . We demonstrated that mean ADC values were most likely to increase in the area directly adjacent to the resection cavity (0-5 mm), while moving further away, the changes quickly became less pronounced. The highest infiltrating tumour load is also to be expected in the 0-5 mm area. The demonstrated heterogeneity of the skewness and kurtosis postradiotherapy might possible be also explained by this higher a priori tumour load as well as heterogeneity in tumour response most pronounced in this area were most tumour is present.
Although a histological correlation has not been performed in this study, previous research has validated the correlation between ADC values and viable tumour cells in rats [7, 9] and humans [9] with glioblastoma. Furthermore, ADC changes preceded contrast enhancement in tumour recurrence indicating the recurrence of tumour cells before these cells induce a disruption of the blood-brain barrier [19] . Observed increase in ADC values after treatment therefore indicate a reduction of tumour cellularity due to radiotherapy.
Reduction of tumour cell density in the direct peritumoural area is of specific interest. Radiotherapy currently targets the resection site and the adjacent region, which was also the case for the patients in our study in combination with chemotherapy. However, this is insufficient as recurrence is still inevitable and occurs in about 90% of the patients within or directly adjacent to the resection area [3] . Low ADC indicative of a high amount of tumour cells in recurrent glioblastoma seen in 95% within the 60 Gy isodose line is associated with poorer outcome [20] . This might be due to the variable treatment response of glioblastoma cells [8] , which is also suggested by our increased standard deviation postradiotherapy. Even more focus on localised therapy thus seems logical and therapy like
Carmustine wafers is of interest [21] . In these cases, however, one would expect to see a survival benefit in patients with ADC response, which we were unable to demonstrate. Our absent correlation with survival might be due to the small group size and could also be partially influenced by treatment given after finishing chemoradiotherapy and tumour progression. However, others have clearly demonstrated a correlation between an increase in ADC values after treatment and outcome. Studies in glioblastoma patients with mixed nonsurgical treatment showed that ADC in the high T2 region differs in patients with progression of the T2 and patients with stable T2 disease [22] .
The same holds for the contrast enhancing area [10, 23] and FLAIR area [10] . However, others demonstrate no correlation with ADC values after treatment but instead demonstrated a correlation of midtreatment ADC values with survival [24] . The correlation with survival is demonstrated for preradiotherapy ADC values in the FLAIR region correlating with progression free survival and overall survival in patients with glioblastoma, most of them with a subtotal resection [25] . Preradiotherapy ADC values also might be more accurate than direct postoperative values due to minor areas with lower ADC values directly postoperative caused by minor ischemic changes. As our ADC postoperative is slightly higher in the 0-5 mm area in comparison to preradiotherapy ischemic changes is unlikely to have influenced postoperative values. Ischemic changes would not be a confounding factor in the preradiotherapy scans as they were all acquired >14 days (mean 21 days) after the operation, at which time any restricted diffusion secondary to ischaemic changes would normalise.
One of the main future applications of ADC response would be the early stratification of patients into responders and nonresponders. This would provide more time for secondary therapeutic interventions, which increases their chance of being effective. It also could prevent unnecessary ineffective, possible toxic and costly treatment in non-responders. Anatomical MRI using the increase in tumour size is incapable of demonstrating early changes. As a result, research has focussed on apparent diffusion coefficients calculated from diffusion weighted MRI. We are the first to show the increase of ADC specific to the area adjacent to the resection as result of chemoradiotherapy after the end of radiotherapy. Others have shown that ADC is also capable of demonstrating an early change in a population with mixed brain tumour [5] and in a rat model with glioblastoma [7, 8] . ADC is thus a potential early imaging biomarker of treatment response. Further research should focus on periresectional ADC values in glioblastoma patients early in the current standard treatment, but also in studies investigating new localised therapies.
In such research, voxel-based ADC response parameters are likely to be more accurate than a single posttreatment measurement and parametric response maps have been shown to outperform a single posttreatment measurement for the prediction of outcome at 3 months and 1 year in treated glioblastoma patients [26] . A parametric response map, however, needs 3D volumetric acquisitions pre-and posttreatment. This is often not acquired as standard in clinical practice. Our more simplified histogram calculations using 2D MRI data therefore has wider applicability. We also used MRI scanners of different manufactures and field strengths. To overcome the known variation that can result from this [27] , we successfully used ADC values normalised to the contralateral normal appearing white matter. This is also an advantage for the applicability of histogram ADC response calculations in clinical practice, in which one also have to deal with different MRI scanners and different ADC settings with most commonly used 2D acquisitions.
Nevertheless, voxel-based ADC analysis in glioblastoma patients are in line with our histogram results, although previous studies have not looked specifically at the periresection area. A comparable patient population of which most also received surgery showed higher ADC values posttreatment [24] . Others have shown similar results in patients without surgery treated with radiotherapy or chemotherapy [5] and boron neutron capture therapy [6] at the location of the primary tumour. An increase of ADC values postradiotherapy in comparison with preradiotherapy values in the contrast enhancing tumour and in the area with high T2 signal was also been demonstrated [10, 11] .
A few limitation can be identified in our study. The relatively small sample size and absence of a correlation with survival in our study has been discussed above. Another limitation is the lack of histological confirmation. However, a higher viable tumour load has been confirmed to correspond with lower ADC values in glioblastoma patients previously [9] making that we can interpreted our ADC values as representing tumour load as also describe in the second paragraph of the discussion.
CONCLUSIONS
In conclusion, we calculate ADC response in the periresection area and showed an increase in ADC postradiotherapy. This has not been demonstrated previously in the periresectional region, but is in line with studies looking at the large areas with high T2 showing a higher ADC posttreatment in correlation with a better outcome.
